We hypothesised that ALK-driven NB, which often involves MYCN amplification, may also represent a situation where cancer cells are more dependent on the integrity of ATR-regulated checkpoint responses and therefore sensitive to ATR inhibitors. The gene discussed is MYCN; the disease is neuroblastoma.